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Virus versus antibody
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Variation in the proteins produced by animal viruses
allows the virus to reinfect the same host, but is
constrained by the requirement to maintain critical viral
functions, in particular engagement with cellular
receptors. The fundamental characteristics of proteins
and their interactions with each other suggest that this
may not be so much of a constraint at all.
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Antigenic variation permits a virus to reinfect its host.
Structural studies of the influenza virus and of rhinoviruses
reveal a separation between antigenically variable and
functionally conserved sites. If antibodies were directed at
the conserved sites of the virus, reinfection could not occur.
So, how do viruses conceal functionally critical structural
elements from surveillance by the host’s antibodies?
Antibodies and viral proteins
A structural solution to this problem was proposed in 1983,
when the structure of influenza virus neuraminidase, an
antigen embedded in the viral envelope, was first
described [1]. Three possible explanations were proposed
that might allow for the preservation of the functionally
important catalytic centre in the face of immune selection
pressure [1]. Firstly, it was proposed that the catalytic site
is inaccessible to antibodies (Fig. 1a); this proposal was
subsequently popularized as the ‘canyon hypothesis’ [2].
It stemmed from the observation that the neuraminidase
active site, like most enzyme centres, is an invaginated
structure. Antibody penetration of that site seems unlikely,
as it did for the canyon-like structure of rhinoviruses. The
second proposal suggested that the site is accessible to
antibodies, but only in such a way that catalytically
nonessential amino acids also form part of the antigen–
antibody complex (Fig. 1b). The central idea here is that
the ‘antibody footprint’ is larger than the functional site on
the virus, so it must therefore extend to include function-
ally unimportant amino acids on the virus. Because a single
amino acid substitution can effectively abolish an
antibody–antigen interaction, mutations outside the func-
tional site allow the virus to escape from an antibody
whilst preserving viral function. At the time these propos-
als were made [1], although the structures of antibodies in
complex with macromolecular antigens were unknown,
the likely size of the interacting surface could be esti-
mated from the known structure of the complementarity-
determining regions of an antibody — the region of
amino-acid sequence that is hypervariable and forms part
of the antigen-binding site. This area was found to be of
the order of 700Å2, a figure reminiscent of other protein–
protein interactions but larger than the active sites of
enzymes. The first high-resolution structural studies of
antibodies in complex with proteins (lysozyme [3] and
influenza virus neuraminidase [4,5]) substantiated this
estimate, supporting the view that the size of the interact-
ing surface — the antibody footprint — is a characteristic
weakness of the antibody system that viruses might
exploit. The third proposal was that the catalytic site is not
antigenic; at the time there existed the possibility that the
viral enzymes had identical active-site structures to those
of host enzymes, and this might have rendered the
catalytic site somehow unrecognizable by antibody.
The canyon hypothesis [2] implicated an invaginated
surface on rhinoviruses in receptor binding, and this
Figure 1
Antibody–virus interactions. (a) Schematic
showing an antibody unable to penetrate an
invaginated surface structure on a viral
protein. The functionally important
(antigenically invariant) surface on the viral
protein is indicated (blue), as is the antigen-
binding surface of the antibody (red).
(b) Schematic showing an antibody
interacting with all of the conserved elements
of a viral protein, but also overlapping with
functionally unimportant amino acids on the
viral protein. Colouring as in (a).
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aspect of the hypothesis has been substantiated by elec-
tron microscope images [6] of rhinovirus in complex with
its cognate cellular receptor [6]. However, it now emerges
that antibodies can also bind in the canyon [7], so the
issue of antibody surveillance in this case has shifted back
to the antibody footprint argument [7]. A structural
description of an influenza haemagglutinin–antibody
complex has also relied upon that argument to rationalize
the preservation of the receptor-binding sites of
influenza virus [8].
Although the presence of an enzyme activity on the surface
of a virus is uncommon (but well characterized for
orthomyxoviruses and paramyxoviruses), all viruses have
some form of surface binding site for cellular receptors.
These receptors range from simple sugars (e.g. sialic acid
— in the context of its linkage stereochemistry — in the
case of influenza virus) to macromolecules (e.g. ICAM-1 for
rhinoviruses, or CD4 for HIV). In the latter cases, where
protein–protein interactions are involved, it is plausible to
consider that the receptor footprint on the virus might be
as large as, or larger than, an antibody footprint. 
Are viruses restricted in their design so that functionally
important structural elements are either smaller than anti-
body-binding sites or sterically inaccessible to antibodies?
Probably not. Three lines of evidence, taken together,
suggest a mechanism for viral survival even in cases, for
example, where the receptor-binding region on the virus is
both larger than an antibody footprint and highly accessible
to antibody. 
Monoclonal variants
The first line of evidence is from in vitro antibody-selected
viral variants. These variants show that subtle stereochemi-
cal alterations (e.g. serine to alanine) within the antibody-
binding site can allow the virus to escape neutralization [9].
On the other hand, quite dramatic amino acid substitutions
(e.g. isoleucine to arginine) within the antibody-binding
site are sometimes tolerated by antibodies [9,10]. The
ability of the antibody to bind where there is an Ile→Arg
substitution on the antigen, depends on the structural plas-
ticity in the antibody–antigen interface. In this case in par-
ticular, not only does an antibody residue shift by 1.3Å with
respect to its position in the wild-type complex, but also
the substituted arginyl residue on the antigen is shifted by
nearly 3Å from its position in the uncomplexed mutant
[10]. The effect of any given amino acid substitution within
an interface depends on the structural context of the substi-
tution. There are obvious parallels in the need to consider
structure in evaluating the effects of mutation both on
protein–protein interactions and on protein folding.
The energetic epitope
The second line of evidence suggesting that viral design is
not constrained by antibody-binding considerations comes
from various approaches to estimating the residue-by-
residue contributions to the binding energy of a
protein–protein complex. The results of alanine-scanning
mutagenesis [11] imply that fewer than half of the amino
acids within a hormone–receptor binding interface con-
tribute significantly to complex formation. Mutagenesis of
influenza neuraminidase amino acids located in the
binding site of the NC41 antibody showed that antibody
binding was more tolerant of substitution at some sites
than at others [12].
Computational approaches to this problem also suggest
the existence of an ‘energetic’ subset of all interface
residues. The calculated contributions to the binding
energy in several different antibody–antigen interac-
tions [13] suggest that few residues contribute most of the
interaction energy, although the sum of the computed
residue-by-residue interaction energies often does not
agree with measurements of the association constants.
Nevertheless, the trends observed from experimental
mutagenesis have been captured in some calculations [14].
One target, two bullets
The third line of evidence against antibody-imposed
viral constraints is provided by the analyses of situations
where two different proteins or protein surfaces bind a
common target surface. Familiar examples of such situa-
tions are: firstly, two different antibodies in an antiserum
binding the same site on an antigen; secondly, an anti-
body (Ab1) that binds both to its cognate antigen and to
anti-idiotopic antibodies (Ab2) raised against it; and
thirdly, an antibody raised to a pathogen antigen which
cross-reacts with host antigen, as in some auto-immune
diseases. In such cases, it is instructive to consider the
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Figure 2
Schematic showing a surface of seventeen amino acids on a viral protein
that form the interface with both the viral receptor and an antibody. Red
residues contribute most of the binding energy for the receptor, and blue
residues for the antibody. Mutations elsewhere are permissive.
similarity between the two surfaces that bind the
common third surface. 
Examination of the three-dimensional structures of two
different antibodies in complex with a common target area
on influenza neuraminidase [15] suggested that the anti-
bodies are dissimilar, in the sense that antigen residues are
not always in the same type of chemical environment in
the two antibody complexes. A study of the electrostatic
interactions in these two complexes [16] has also con-
cluded that although both complexes display a measure of
electrostatic complementarity, which is similar to that
found in other protein–protein complexes, there is no sim-
ilarity in the electrostatic potentials of the two antibodies,
implying that the complementarity of the two complexes
involves different surface patches within the antigen inter-
face. This suggests that at least the electrostatic contribu-
tion to the binding energy of the two complexes is
differently distributed among the neuraminidase residues
common to the two complexes.
An anti-idiotope (Ab2)–antibody (Ab1) complex has been
compared structurally with an antigen (lysozyme)–antibody
(Ab1) complex, leading to the conclusion that similar
binding interactions occur in the two complexes [17], but
only over the hydrophilic parts of the interface [18].
Alanine-scanning mutagenesis of the anti-lysozyme anti-
body (Ab1) has found that the antibody interacts with
lysozyme and the anti-idiotypic antibody through two dif-
ferent ‘energetic’ subsets of residues [19]. In two cases,
alanine substitutions on Ab1 reduce the binding affinity to
the anti-idiotope by more than 4kcalmol–1, whereas the
reduction in antigen-binding affinity is approximately
0.5kcal mol–1. A third example reduces binding to antigen
by 2.7kcalmol–1, whereas a reduction in anti-idiotope
binding is by only 0.3kcalmol–1.
The results of both of these studies [16,17] point to the
existence of mutations in the common target surface that
will compromise one of the two interactions in question,
but leave the other essentially unaffected (Fig. 2).
Conclusion
Thus, antibodies may select amino acid substitutions on
the viral protein which can compromise binding with that
particular antibody, but have no effect on receptor
binding, even though the receptor- and antibody-binding
sites are otherwise identical. On this basis, it is unneces-
sary for functional sites on viral proteins to be restricted in
any way, either by size or by location, because antibody
surveillance of such sites on rapidly mutating viruses is
fundamentally compromised by the very nature of
protein–protein interactions. Only in cases where the anti-
body and the receptor bind to the virus in energetically
identical ways will the potential of the virus to evade
antibody surveillance be threatened.
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